Eiger BioPharmaceuticals, Inc.
NASDAQ:EIGR
1.73 (USD) • At close September 17, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Eiger BioPharmaceuticals, Inc. |
Symbool | EIGR |
Munteenheid | USD |
Prijs | 1.725 |
Beurswaarde | 2,552,120 |
Dividendpercentage | 0% |
52-weken bereik | 1.1 - 43.35 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. David Apelian M.B.A., M.D., MBA, Ph.D. |
Website | https://www.eigerbio.com |
An error occurred while fetching data.
Over Eiger BioPharmaceuticals, Inc.
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)